The Technical Analyst
Idera Pharmaceuticals, [IDRA]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
Idera Pharmaceuticals, Price, Forecast, Insider, Ratings, Fundamentals & Signals
-23.04% $0.425
/ 17 jan 2023 @ 16:00
| RATING 2023-01-31 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.391 - 0.459 ( +/- 8.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-08-10 | Gowen Maxine | Sell | 51 | Common Stock |
| 2023-08-10 | Milano Vincent | Sell | 3 283 | Common Stock |
| 2023-05-17 | Pillar Invest Corp | Buy | 26 965 | Common Stock |
| 2023-07-12 | Pillar Invest Corp | Sell | 3 605 | Common Stock |
| 2023-07-13 | Pillar Invest Corp | Sell | 2 213 | Common Stock |
| INSIDER POWER |
|---|
| 84.22 |
| Last 89 transactions |
| Buy: 5 449 477 | Sell: 354 169 |
Forecast:
01:40 - $0.355
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.425 (-23.04% ) |
| Volume | 0.372 mill |
| Avg. Vol. | 0.0340 mill |
| % of Avg. Vol | 1 093.21 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IDRA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IDRA
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
Latest Press Releases
2021-08-09 16:15:00 - Press Release
Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results And Provides Corporate Update
Exton, pa., aug. 09, 2021 (globe newswire) -- idera pharmaceuticals, inc. (“idera” or the “company”) (nasdaq: idra) today reported its financial and operational results for the second quarter ended june 30, 2021.
2021-05-18 16:15:00 - Press Release
Idera Pharmaceuticals Announces Corporate Updates
Exton, pa., may 18, 2021 (globe newswire) -- idera pharmaceuticals, inc. (“idera” or the “company”) (nasdaq: idra) today announced that it will not continue illuminate-301, the company's trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-pd-1 refractory advanced melanoma, to its overall survival (os) primary endpoint. the company reported in march 2021 that the trial did not meet its primary endpoint of objective response rate (orr). full results from the study will be presented in a future publication.
2021-04-29 16:10:00 - Press Release
Idera Pharmaceuticals Reports First Quarter 2021 Financial Results And Provides Corporate Update
Exton, pa., april 29, 2021 (globe newswire) -- idera pharmaceuticals, inc. (“idera” or the “company”) (nasdaq: idra) today reported its financial and operational results for the first quarter ended march 31, 2021.
2021-03-18 16:15:00 - Press Release
Idera Pharmaceuticals Announces Results From Illuminate-301 Trial Of Tilsotolimod + Ipilimumab In Anti-pd-1 Refractory Advanced Melanoma
– objective response rate endpoint not met – – objective response rate endpoint not met –
2021-03-01 16:35:00 - Press Release
Idera Pharmaceuticals Reports Fourth Quarter And Full Year 2020 Financial Results And Provides Corporate Update
Illuminate-301 continues on track for data later this month illuminate-301 continues on track for data later this month
Latest News
2022-05-21 13:00:00 - PennyStocks
Buying Penny Stocks Right Now? 3 Top Tips to Know
What you need to know about trading penny stocks right now The post Buying Penny Stocks Right Now? 3 Top Tips to Know appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-05-18 16:11:05 - PennyStocks
3 Penny Stocks That Are Climbing During Today's Market Selloff
Are these three penny stocks on your watchlist right now? The post 3 Penny Stocks That Are Climbing During Today's Market Selloff appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-05-17 12:05:12 - Benzinga
Why Are Idera Pharmaceuticals Shares Soaring Today
Idera Pharmaceuticals Inc (NASDAQ: IDRA) shared positive interim results from its investigator-sponsored Phase 2 trial, INTRIM 1, involving tilsotolimod, Idera's synthetic Toll-like receptor 9 agonist. Based on these results, the trial has been stopped early.
2022-04-19 13:45:25 - PennyStocks
5 Top Biotech Penny Stocks Under $1 To Watch This Week
Top penny stocks to watch under $1 in April if you like Biotech stocks. The post 5 Top Biotech Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-01-04 14:27:18 - PennyStocks
Hot Penny Stocks For 2022 To Buy For Under $2
Penny stocks to buy for under $2 The post Hot Penny Stocks For 2022 To Buy For Under $2 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-12-08 14:26:06 - PennyStocks
5 Penny Stocks To Buy According To Analysts & Targets Up To 341%
2021-08-09 16:15:00 - GlobeNewsWire
Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
EXTON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2021.
2021-06-22 04:33:19 - Pulse2
IDRA Stock Price Increases Over 20% Pre-Market: Why It Happened
The stock price of Idera Pharmaceuticals Inc (NASDAQ: IDRA) increased by over 20% pre-market. This is why it happened.
2021-05-18 16:15:00 - GlobeNewsWire
Idera Pharmaceuticals Announces Corporate Updates
EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today announced that it will not continue ILLUMINATE-301, the Company's trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, to its overall survival (OS) primary endpoint. The Company reported in March 2021 that the trial did not meet its primary endpoint of objective response rate (ORR). Full results from the study will be presented in a future publication.
2021-04-29 16:10:00 - GlobeNewsWire
Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
EXTON, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2021.